NCT03244072

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 60,000 (estimated)
• Sponsor: Jason Ahee, M.D. · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Accepted

Summary

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Detailed description

Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.

Conditions

• Endophthalmitis

Interventions

Type	Name	Description
DRUG	Moxifloxacin	Intracameral injection
DRUG	Placebo	intracameral injection

Timeline

• Start date: 2026-06-01
• Primary completion: 2030-10-01
• Completion: 2031-10-01
• First posted: 2017-08-09
• Last updated: 2025-09-25

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study